Getinge has acquired Paragonix Technologies, Inc. for an undisclosed amount, in a move that expands Getinge's footprint in medical technology. Paragonix Technologies, based in Waltham, MA, is a rapidly growing medical device manufacturer specializing in advanced organ transplant transport devices. The company designs, manufactures, and sells technologies such as the SherpaPak Cardiac Preservation and LUNGguard Organ Preservation systems, committed to ensuring optimal preservation for donor organs from procurement to transplant.
Paragonix's portfolio includes a comprehensive suite of preservation solutions for various organs, including heart, lung, kidney, and liver. Beyond its physical devices, Paragonix offers intuitive digital services for real-time location tracking and temperature monitoring of donor organs, coupled with 24/7 clinical support. This integration of advanced preservation technology with digital logistics and support services positions Paragonix as a key innovator in improving transplant outcomes. For Getinge, a global provider of medical technology, this acquisition represents a strategic entry into the organ preservation market, complementing its existing offerings.
The acquisition is expected to create significant synergies by combining Paragonix’s specialized organ preservation expertise with Getinge’s broader global distribution network and established presence in critical care and life sciences. This will allow the combined entity to reach more transplant centers globally and accelerate the adoption of advanced preservation technologies. Getinge can leverage Paragonix’s innovative solutions to offer a more complete suite of products to healthcare professionals, ultimately aiming to enhance patient care and expand market reach within the transplant community.
Looking ahead, the integration of Paragonix Technologies into Getinge is anticipated to strengthen its position as a comprehensive partner for transplant teams worldwide. The combined capabilities are expected to drive further advancements in organ transplantation, focusing on improved preservation, logistics, and outcomes for donor organs and transplant recipients. The acquisition is poised to accelerate the development and deployment of next-generation solutions in this critical area of medical treatment.